Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

CNC · Q4 2025 Earnings

Centene Corporation

Reported February 6, 2026

30-second summary

Centene posted FY2025 adjusted EPS of $2.08, above the ≥$2.00 floor set in October, with Q4 Medicaid HBR landing at 93.0% — a 40bp sequential improvement off Q3's 93.4% and well inside the back-half trajectory. The headline is the FY2026 guide: adjusted EPS >$3.00 (≥44% growth), premium and service revenues of $170–174B, and a consolidated HBR of 90.9–91.7% — a roughly 260–340bp implied snapback from Q4's 94.3%. The setup is credible but unforgiving: management has now bound itself to both margin recovery and earnings power restoration on the same call where it disclosed a Q4 GAAP loss of $2.24/share and a $1.1B net loss.

Headline numbers

EPS

Q4 FY2025

$-1.19

Revenue

Q4 FY2025

$49.73B

+21.9% YoY

Operating margin

Q4 FY2025

-3.5%

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$49.73B	+21.9%	$49.69B	+0.1%
EPS	$-1.19	—	$0.50	-338.0%
Operating margin	-3.5%	—	-14.0%	+1049bps

Guidance

Affirmed FY2025 EPS beat ($2.08 vs. $2.00 guide) while launching FY2026 guidance signaling sharp margin recovery: adjusted EPS >$3.00 (44% growth), HBR 90.9–91.7% (vs. 94.3% in Q4), premium revenues $170–174B, and SG&A 7.1–7.7%.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Adjusted Diluted EPS	FY 2025	at least $2.00	$2.08	+$0.08 above guide	Beat

New guidance

Metric	Period	Guide	YoY
Revenue	FY 2026	$186.5 billion to $190.5 billion	—
Adjusted Diluted EPS	FY 2026	> $3.00	—
Premium and Service Revenues	FY 2026	$170.0 billion to $174.0 billion	—
Health Benefits Ratio (HBR)	FY 2026	90.9% to 91.7%	—
SG&A Expense Ratio	FY 2026	7.1% to 7.7%	—
Adjusted SG&A Expense Ratio	FY 2026	7.1% to 7.7%	—
Effective Tax Rate	FY 2026	27.0% to 28.0%	—
Adjusted Effective Tax Rate	FY 2026	26.0% to 27.0%	—
Diluted Shares Outstanding	FY 2026	495.6 million to 498.6 million	—

Segment KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
Medicaid	$23.045B	+11.0%
Commercial	$10.792B	+24.0%
Medicare	$9.61B	+75.0%
Other	$1.28B	+1.0%

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
Health Benefits Ratio (HBR)	94.3%
Medicaid HBR	93.0%
Commercial HBR	95.4%
Medicare HBR	96.1%
SG&A Expense Ratio	7.5%
Total At-Risk Membership	27,633,500
Medicaid Membership	12,518,400
Days in Claims Payable	46 days

Management tone

Q2 capitulation ($5.50 EPS cut, "unacceptable") → Q3 measured optimism with policy hedging → Q4 commitment to a 44%+ EPS rebuild and a 300bp HBR snapback.

The Medicaid framing has shifted from "fixable over 4–6 quarters" (Q2) to "consistent with 2025" (Q3) to a quantified FY2026 HBR guide of 90.9–91.7% that, on a consolidated basis, implies a ~300bp reduction off the Q4 94.3% print. Management's prepared-remarks anchor — "We expect full year 2026 adjusted diluted EPS to be greater than $3.00, marking important progress toward restoring the enterprise's embedded earnings power" — moves the narrative from stabilization to restoration. The word "restoring" is doing real work: it implicitly concedes FY2025 was a trough and that the $7.25 original 2025 guide represented something close to true earnings power that management now believes it can rebuild toward.

The Marketplace pivot is now codified rather than aspirational. Q2 framed the segment as broken and underpriced; Q3 framed it as repriced and ready; Q4's premium and service revenue guide of $170–174B — versus FY2025's $194.8B total revenue — embeds the planned membership shedding. The qualitative shift to "meaningful pre-tax margin expansion in 2026 and compared to losing approximately 1% in 2025" turns a loss-making segment into a 2026 earnings contributor, which is the lynchpin of the >$3.00 EPS bridge.

Medicare Advantage is moving forward in time. Q3 framed 2027 breakeven as the goal; Q4 management characterises FY2026 as "not quite a break even yet... no PDR in 2026 means that on the margin, it's not losing money." A no-PDR posture for 2026 is a stronger statement than the previous "approaching breakeven" framing, even if breakeven itself remains a 2027 event.

The rate environment narrative has matured from "structurally lagging" to "organically catching up." Management now describes the two-year actuarial lookback as having the 2024 acuity shifts and 2025 trend impact "basically sitting in the middle" of the standard window — a structural argument that Medicaid rate adequacy improves mechanically as time passes, independent of new advocacy wins.

The one tone shift that materially adds risk is the No Surprises Act framing. Calling NSA "weaponized by market participants looking to extract profits" and disclosing a multimillion-dollar lawsuit against a New York provider reclassifies what was a regulatory cost of doing business into an active litigation front. This is a chastened company — the CEO's "If all we do is deliver a 93.7 in Medicaid, I will be very disappointed" indicates internal targets above the FY guide, but also that prior credibility losses require the company to over-deliver to be believed.

Recurring themes management leaned on this quarter:

Medicaid trend stabilization via multi-lever intervention (networks, clinical programs, fraud detection, program reform)Marketplace margin recovery through aggressive repricing and risk repositioning post-EAPTC expirationMedicare Advantage progression toward near-breakeven ahead of 2027 targetData, AI, and automation as enterprise-wide margin expansion accelerantsProactive state engagement to shorten rate lookback periods and incorporate emerging acuity dataRate advocacy and program reform as co-equal tools to rate increases in cost management

Risks management surfaced:

Continued policy-related variability and program uncertainty (work requirements, eligibility changes, benefit design shifts)No Surprises Act litigation costs and IDR process manipulation creating margin headwindsMedicare 2027 advance notice rate pressure cutting into senior benefits and product selectionRisk adjustment volatility in Marketplace (noted as source of significant deviation in 2025)Bronze plan utilization volatility and member trade-down patterns in Marketplace post-EAPTC

Answers to last quarter's watch list

Q4 Medicaid HBR vs the ~93.2% back-half trajectory — Q4 Medicaid HBR came in at 93.0%, a 40bp sequential improvement off Q3's 93.4%, beating the trajectory. The Florida retro benefit that helped Q3 didn't repeat, so this is underlying improvement rather than a timing tailwind.

Resolved positively

2026 initial EPS guide framing in February — Management quantified adjusted EPS at >$3.00 (≥44% growth) with a consolidated HBR guide of 90.9–91.7% — a 260–340bp implied step-down versus Q4's 94.3%. Marketplace is explicitly guided to "meaningful pre-tax margin expansion" vs the ~1% loss in 2025, and Medicare to a no-PDR position. The Medicaid 2026 anchor is well above the "consistent with 2025" floor, embedded in the HBR guide.

Resolved positively

Marketplace reserve release or build in Q4 — Days in claims payable fell to 46 from 48 at Q3, a modest reserve drawdown across the consolidated book. The press release doesn't separately disclose the $200M EAPTC contingency disposition; the call transcript would clarify but isn't available for this print.

Continue monitoring

PDP 2026 pre-tax margin guide — Press release does not isolate PDP segment margin guidance; the disclosure framework only quantifies consolidated HBR and SG&A.

Continue monitoring

EAPTC policy resolution and open enrollment breakage — Management's hedging language ("we have prudently positioned our 2026 outlook incorporating an expectation that policy-related variability will continue") indicates EAPTC expiration is baselined into the guide, not resolved by policy action. The premium and service revenue guide of $170–174B implies meaningful Marketplace shedding consistent with the high-teens-to-mid-30s contraction band.

Continue monitoring

GAAP-to-adjusted bridge — Q4 GAAP EPS of $(2.24) vs adjusted EPS of $(1.19) is a $1.05 spread, far smaller than Q3's $14.00 impairment-driven gap. The FY2026 guide of GAAP EPS >$1.98 vs adjusted EPS >$3.00 implies an ongoing ~$1.00+ recurring adjustment run-rate — material and worth tracking as recovery progresses. Status: Resolved negatively (the adjustment gap is structural, not one-time)

What to watch into next quarter

Q1 Medicaid HBR vs the 90.9–91.7% FY guide midpoint of ~91.3% — the consolidated guide implies a roughly 300bp snapback off Q4 94.3%; Q1 needs to print meaningfully better than Q4 to make the math credible. A Q1 consolidated HBR above 93% puts the FY guide at risk

Marketplace pre-tax margin progression — management committed to "meaningful pre-tax margin expansion" in 2026 from a -1% 2025 loss. First read on the repriced book lands in Q1; watch whether commercial HBR drops from 95.4% toward something below 88%

Medicare Advantage PDR position — management characterised 2026 as "not quite breakeven" with "no PDR" booked. Any reintroduction of a premium deficiency reserve mid-year would materially shift the 2027 breakeven path

NSA litigation escalation — the New York provider lawsuit is the first; watch for additional filings and any quantification of IDR-related margin drag in quarterly disclosures

Buyback cadence against 495.6–498.6M share guide — the diluted share count guide implies modest reduction; watch repurchase pace relative to the ~503M baseline as a read on capital allocation discipline post-impairment

Sources

Centene Q4 FY2025 press release, February 6, 2026 (SEC filing)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.